J 
Japan Animal Referral Medical Center Co 6039.T · JPY
Health Care · Tokyo Stock Exchange · 🇯🇵 Japan
876
+2.34%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥6.19bn
FY2017FY2026
Net income
¥833.4m
FY2017FY2026
Free cash flow
−¥953.4m
FY2017FY2026
Shareholders' equity
¥4.88bn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥6.19bn | ¥5.28bn | ¥4.27bn | ¥3.87bn | ¥2.98bn | ¥2.85bn | ¥2.73bn | ¥2.56bn | ¥2.26bn | ¥2.19bn |
| Gross profit | ¥2.51bn | ¥1.81bn | ¥1.43bn | ¥1.41bn | ¥1.07bn | ¥977.1m | ¥991.9m | ¥907.8m | ¥766.6m | ¥772.2m |
| Research and development | — | ¥8.9m | ¥7.5m | ¥7.0m | — | — | — | ¥100,000 | ¥2.5m | ¥4.5m |
| Operating income | ¥1.15bn | ¥721.0m | ¥496.9m | ¥584.9m | ¥439.3m | ¥405.5m | ¥430.7m | ¥397.2m | ¥280.0m | ¥294.3m |
| Net income | ¥833.4m | ¥521.0m | ¥337.2m | ¥380.7m | ¥286.9m | ¥285.2m | ¥312.8m | ¥294.9m | ¥208.1m | ¥229.4m |
| Diluted earnings per share | 64.48 | 40.31 | 26.06 | 27.24 | 23.81 | 23.35 | 25.33 | 23.42 | 16.50 | 18.28 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥11.31bn | ¥8.75bn | ¥8.77bn | ¥8.58bn | ¥7.11bn | ¥5.84bn | ¥5.93bn | ¥6.09bn | ¥5.94bn | ¥5.13bn |
| Cash and short-term investments | ¥1.59bn | ¥1.11bn | ¥1.34bn | ¥1.92bn | ¥1.07bn | ¥1.21bn | ¥1.25bn | ¥1.25bn | ¥890.3m | ¥858.3m |
| Total liabilities | ¥6.43bn | ¥4.61bn | ¥4.96bn | ¥4.87bn | ¥4.60bn | ¥3.51bn | ¥3.79bn | ¥4.27bn | ¥4.41bn | ¥3.90bn |
| Debt | ¥5.16bn | ¥3.48bn | ¥3.86bn | ¥3.98bn | ¥3.92bn | ¥3.07bn | ¥3.40bn | ¥3.83bn | ¥4.11bn | ¥3.61bn |
| Shareholders' equity | ¥4.88bn | ¥4.15bn | ¥3.81bn | ¥3.71bn | ¥2.51bn | ¥2.34bn | ¥2.13bn | ¥1.83bn | ¥1.53bn | ¥1.23bn |
| Shares outstanding | 13m | 13m | 13m | 14m | 12m | 12m | 12m | 13m | 13m | 13m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥1.40bn | ¥1.37bn | ¥899.8m | ¥810.9m | ¥557.6m | ¥504.4m | ¥538.0m | ¥741.4m | ¥344.4m | ¥428.6m |
| Capital spending | −¥2.35bn | −¥953.7m | −¥1.04bn | −¥728.3m | −¥601.7m | −¥65.5m | −¥68.9m | −¥97.6m | −¥787.7m | −¥1.08bn |
| Free cash flow | −¥953.4m | ¥418.7m | −¥141.3m | ¥82.6m | −¥44.1m | ¥438.9m | ¥469.1m | ¥643.8m | −¥443.3m | −¥656.1m |
| Dividends paid | −¥100.5m | −¥53.6m | — | — | — | — | — | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.64bn | ¥1.53bn | ¥1.63bn | ¥1.56bn | ¥1.47bn | ¥1.34bn | ¥1.37bn | ¥1.32bn |
| Gross profit | ¥701.4m | ¥600.1m | ¥696.7m | ¥647.5m | ¥563.0m | ¥421.8m | ¥519.8m | ¥463.9m |
| Operating income | ¥349.3m | ¥183.4m | ¥375.8m | ¥332.3m | ¥258.8m | ¥130.8m | ¥239.3m | ¥201.6m |
| Net income | ¥239.7m | ¥158.2m | ¥262.0m | ¥233.0m | ¥180.3m | ¥111.8m | ¥166.4m | ¥139.8m |
| Diluted earnings per share | 18.55 | 12.24 | 20.27 | 18.03 | 13.95 | 8.65 | 12.86 | 10.80 |
| Total assets | ¥11.24bn | ¥11.31bn | ¥9.27bn | ¥9.03bn | ¥9.09bn | ¥8.75bn | ¥8.63bn | ¥8.56bn |
| Cash and short-term investments | ¥1.25bn | ¥1.59bn | ¥1.22bn | ¥1.15bn | ¥1.22bn | ¥1.11bn | ¥1.03bn | ¥928.5m |
| Debt | ¥2.52bn | ¥5.16bn | ¥713.1m | ¥3.47bn | ¥1.08bn | ¥3.48bn | ¥645.6m | ¥3.82bn |
| Shareholders' equity | ¥4.96bn | ¥4.88bn | ¥4.72bn | ¥4.46bn | ¥4.23bn | ¥4.15bn | ¥4.04bn | ¥3.87bn |
Financial ratios
Data as of 28 Sept 2026
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 40.5% | 34.3% | 33.6% | 36.3% | 36.0% | 34.3% | — | — | — |
| Operating margin | 18.6% | 13.7% | 11.6% | 15.1% | 14.7% | 14.2% | — | — | — |
| Net margin | 13.5% | 9.9% | 7.9% | 9.8% | 9.6% | 10.0% | — | — | — |
| Return on equity | 17.1% | 12.6% | 8.8% | 10.3% | 11.4% | 12.2% | — | — | — |
| Return on assets | 7.4% | 6.0% | 3.8% | 4.4% | 4.0% | 4.9% | — | — | — |
| Free cash flow yield | 28.9% | 18.0% | 15.0% | 11.0% | 9.6% | 4.7% | — | — | — |
| Revenue growth | 17.3% | 23.6% | 10.3% | 30.0% | 4.6% | 4.2% | — | — | — |
| Earnings growth | 60.0% | 54.5% | -11.4% | 32.7% | 0.6% | -8.8% | — | — | — |
| Current ratio | 0.56x | 1.03x | 1.16x | 1.89x | 1.59x | 1.59x | — | — | — |
| Debt to equity | 1.06x | 0.84x | 1.01x | 1.07x | 1.56x | 1.32x | — | — | — |
| Equity ratio | 43.1% | 47.4% | 43.5% | 43.2% | 35.3% | 40.0% | — | — | — |
| Interest coverage | 28.81x | 24.06x | 22.49x | 26.78x | 18.14x | 22.81x | — | — | — |
| R&D as a share of sales | — | 0.2% | 0.2% | 0.2% | — | — | 0.0% | 0.1% | 0.2% |
| Buybacks as a share of market value | -0.0% | 0.1% | 7.4% | -16.0% | 1.3% | 1.1% | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 16.9% | 16.8% | 11.5% |
| Operating income | 25.3% | 23.2% | 16.8% |
| Net income | 29.9% | 23.9% | 14.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 37.6% | 36.5% | 36.2% | 35.9% |
| Operating margin | 16.3% | 15.1% | 14.9% | 14.6% |
| Net margin | 11.8% | 10.6% | 10.4% | 10.5% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 14.4 | 29.1 | 18.2 | 12.7 | 16.0 | 15.7 | 17.2 | 19.9 | 25.9 | 32.0 |
| Price to sales | 1.9 | 2.9 | 1.4 | 1.3 | 1.5 | 1.6 | 2.0 | 2.3 | 2.4 | 3.4 |
Dividends and splits
Per share, in the currency the company pays
Paid for 2 years. Last went ex-dividend on 30 Mar 2026.
| FY2026 | FY2025 | |
|---|---|---|
| Paid in the year | 19.40 | 4.00 |
- 5-for-1 split · 15 Dec 2025
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.